Earle A. Chiles Research Institute

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, and a phase I trial for people with AML assesses a non-engineered natural killer cell therapy

New articles co-authored by Dr. Rachel Sanborn feature amivantamab studies for people with NSCLC.

A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.

Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.

SITC 2023 provides a glimpse into scientific advances and breakthroughs in cancer immunotherapy by researchers from around the world.

Two new studies available at Earle A. Chiles Research Institute, at division of Providence Cancer Institute of Oregon, to evaluate new treatments for triple-negative breast cancer.

Providence Cancer Institute of Oregon, and research director, Earle A. Chiles Research Institute, Walter J. Urba, M.D., Ph.D., receives award for his contributions to science and community.

For Gynecologic Cancer Awareness Month, Providence Cancer Institute highlights a clinical trial that evaluates the safety and effectiveness of a new oral treatment for grade 1 endometrial cancer.

New trial open at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, is enrolling patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

A phase II trial tests FOLFOX or CAPOX versus FOLFIRINOX in patients with locally advanced rectal cancer, and a phase I trial evaluates TBio-4101 in patients with advanced solid tumors.

Final outcomes from a Providence Cancer Institute-sponsored phase Ib trial evaluating pembrolizumab with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic TNBC.

Researchers from Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, shared their investigations to advance cancer research and treatments at the premier event.

New investigator-initiated trial at Providence to evaluate a triple combination of medications for treating melanoma, and two new studies evaluating medication combinations to treat AML.

Providence researchers awarded an R21 grant from the National Institutes of Health which provides funding for projects with potential to significantly advance biomedical research.

Studies open at Providence Cancer Institute in Oregon for patients with head and neck cancer and patients with breast cancer that has metastasized in the brain.

New trials available at Earle A. Chiles Research Institute for patients with human epidermal growth factor receptor 2 positive (HER2+) colorectal cancer and patients with cholangiocarcinoma.

A new trial offered at Providence Cancer Institute is enrolling patients with early-stage HR-positive and HER2-negative breast cancer.